SCHEMBL4548043

SCHEMBL4548043

Cc1ccc(NC(=O)Nc2ccc(Cl)cc2)c(C)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.74
MEN1 O00255 6/20 0.74
KMT2A Q03164 6/20 0.74
RAB9A P51151 6/20 0.74
ALDH1A1 P00352 3/20 0.74
MAPT P10636 3/20 0.74
IDH1 O75874 3/20 0.59
CNR1 P21554 1/20 0.57
HTT P42858 4/20 0.54
NPC1 O15118 6/20 0.54
LMNA P02545 3/20 0.54
CXCR2 P25025 1/20 0.54
GRIK1 P39086 1/20 0.54
TP53 P04637 1/20 0.54
GAA P10253 1/20 0.54
RAF1 P04049 1/20 0.53
NLRP1 Q9C000 1/20 0.53
EPHX1 P07099 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
CHRM1 P11229 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13556605 0.91 RAB9A (0.65) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL725553 0.90 IDH1 (0.69) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL4548287 0.90 MEN1 (0.61) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL4548133 0.88 MEN1 (0.61) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL4548128 0.88 RAB9A (0.69) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL6567616 0.86 CXCR2 (0.73) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL11350134 0.85 MEN1 (0.71) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL5853268 0.84 CXCR2 (0.74) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL7823604 0.83 MAPT (0.59) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1
SCHEMBL3026575 0.83 RAB9A (0.70) SMN1; SMN2MEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-11-03 US disclosed
US-9421211-B2 N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-08-23 US disclosed
WO-2012162025-A1 METHODS OF SELECTING CANCER PATIENTS FOR TREATMENT WITH N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-11-29 WO disclosed
US-20120115915-A1 N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-05-10 US disclosed
US-20120115915-A1 N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-05-10 US disclosed
WO-2010138820-A2 N,N-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation NSUN2, EIF2AK2, RNGTT SMN1; SMN2 850/4885MEN1 2936/4885KMT2A 761/4885
US-20120115915-A1 N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION NSUN2, EIF2AK2, RNGTT SMN1; SMN2 850/4885MEN1 2936/4885KMT2A 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.